First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.

by Klaus Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Angelika Stern, Hendrik Gille, Laurent P Audoly, Max E Scheulen
Published 2013-01-01